| Followers | 131 |
| Posts | 15004 |
| Boards Moderated | 0 |
| Alias Born | 06/04/2018 |
Saturday, September 21, 2019 1:50:26 PM
News: $SNY 2 Biotech Stocks I Wouldn't Touch With a Broom
Drug development is a losing game full of highly trained professionals who would rather be lucky than talented at their jobs. This is because experimental new drugs fail so frequently that an entire career without one successful new drug discovery under their belts isn't uncommon. Doing everyth...
Got this from SNY - 2 Biotech Stocks I Wouldn't Touch With a Broom
Drug development is a losing game full of highly trained professionals who would rather be lucky than talented at their jobs. This is because experimental new drugs fail so frequently that an entire career without one successful new drug discovery under their belts isn't uncommon. Doing everyth...
Got this from SNY - 2 Biotech Stocks I Wouldn't Touch With a Broom
Recent SNY News
- Form 13F-HR - Quarterly report filed by institutional managers, Holdings • Edgar (US Regulatory) • 05/07/2026 12:47:00 PM
- Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 • PR Newswire (US) • 05/06/2026 04:42:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/05/2026 10:06:57 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/29/2026 10:04:08 AM
- Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 04/22/2026 09:30:00 PM
- Sanofi devient la détentrice de l'autorisation de mise en marché de Nuvaxovid(MD) au Canada, élargissant ainsi les choix de vaccins contre la COVID-19 pour la population canadienne • PR Newswire (Canada) • 04/09/2026 02:00:00 PM
- Sanofi becomes market authorization holder for Nuvaxovid® in Canada, expanding COVID-19 vaccine choices for Canadians • PR Newswire (Canada) • 04/09/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/31/2026 04:19:10 PM
- Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP) • GlobeNewswire Inc. • 03/24/2026 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/10/2026 02:40:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 05:26:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/03/2026 11:15:15 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2026 02:19:13 PM
- Sanofi announces leadership evolution in Specialty Care Business Unit • PR Newswire (US) • 02/17/2026 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/06/2026 03:09:38 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/05/2026 11:17:47 AM
- Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma • GlobeNewswire Inc. • 12/23/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/03/2025 04:30:33 PM
- Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU) • GlobeNewswire Inc. • 11/25/2025 06:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/18/2025 05:29:51 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2025 04:40:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/31/2025 05:48:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/29/2025 03:15:09 PM
- UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey • GlobeNewswire Inc. • 10/28/2025 12:47:31 AM
